NEW YORK (GenomeWeb) – Although it was one of the first companies to develop methods for highly sensitive sequencing of circulating tumor DNA, Personal Genome Diagnostics has so far limited its liquid biopsy testing to the research market.

That changed last week, though, with the launch of the company's first clinical blood-based cancer sequencing test, PlasmaSelect 64 — a pan-cancer targeted next-gen sequencing assay that offers physicians the opportunity to look for actionable alterations in a patient's tumor without having to do an invasive biopsy.